ArticleCancer science2008
Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer.
Article in Cancer science, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Prognostic significance of NF-κB expression in non-small cell lung cancer: A meta-analysis.PloS one · 2018Pooled it
- NF-κB Expression and Outcomes in Solid Tumors: A Systematic Review and Meta-Analysis.Medicine · 2015Pooled it
- Co-treatment of Colchicine and Rosiglitazone synergistically inhibits cytokine-driven inflammation and modulates the related hsa-miRNA26a-5p, hsa-miRNA21-5p, and STAT3 expression in non-small cell lung cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Comparative whole transcriptome analysis of gene expression in three canine soft tissue sarcoma types.PloS one · 2022Article
- Novel cytoplasmic lncRNA IKBKBAS promotes lung adenocarcinoma metastasis by upregulating IKKβ and consequential activation of NF-κB signaling pathway.Cell death & disease · 2021Article
- Targeting NF-κB mediated cell signaling pathway and inflammatory mediators by 1,2-diazole in A549 cellsBiotechnology reports (Amsterdam, Netherlands) · 2021Article
- Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Mechanistic understanding of β-cryptoxanthin and lycopene in cancer prevention in animal models.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2020Review
- Article
- IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function.Cell cycle (Georgetown, Tex.) · 2019Article
- Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment.Frontiers in oncology · 2019Review
- Aqueous extract of Sapindus mukorossi induced cell death of A549 cells and exhibited antitumor property in vivo.Scientific reports · 2018Article
- Co-expression of NF-κB-p65 and phosphorylated NF-κB-p105 is associated with poor prognosis in surgically resectable non-small cell lung cancer.Journal of cellular and molecular medicine · 2018Article
- Exome and transcriptome sequencing identifies loss ofCancer management and research · 2017Article
- Induction of GOncology letters · 2016Article
- Piperlongumine inhibits lung tumor growth via inhibition of nuclear factor kappa B signaling pathway.Scientific reports · 2016Article
- Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences.Pathology research international · 2015Article
- NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target.Frontiers in bioscience (Landmark edition) · 2011Review
- Blocking NF-κB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death.Apoptosis : an international journal on programmed cell death · 2011Article
- Expression of nuclear transcription factor kappa B in locally advanced human cervical cancer treated with definitive chemoradiation.International journal of radiation oncology, biology, physics · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical relevance of nuclear factor kappaB (NF-kappaB) and its regulatory molecules on prognosis of patient with early stages of non-small cell lung cancer (NSCLC), remains unclear. Therefore, we conducted biomarker analyses with survival in patients with stages I and II NSCLC. Tumor samples were collected from 88 patients with early-stage NSCLC (stages I, II). A minimum follow-up period of 5 years was required. RelA, phosphorylated I kappaB (pI kappaB alpha), pIKK alpha/beta were detected by immunostaining. NF-kappaB DNA binding activity was assessed by electrophoretic mobility shift assay. Association of clinical and pathologic variables (e.g. sex, age, pathologic stage) with relevant molecules was determined by Pearson's chi(2) test or Fisher's exact test. Survival analysis based on single expression of RelA, pI kappaB alpha, pIKK alpha/beta as well as composite expressions were evaluated using Cox proportional hazards regression models, and log rank test followed Kaplan-Meier estimates. RelA, pI kappaB alpha, pIKK alpha/beta were observed as increased expression in NSCLC tissues compared with adjacent normal tissues and normal lung tissues. These molecules were associated with tumor-node-metastasis stages, T stages and histological status, respectively. Among the molecules analyzed, RelA and pI kappaB alpha-positive were statistically significant predictors of patient death in the entire patient population adjusted by age, gender and smoking status; furthermore both RelA and pI kappaB alpha-positive was the strongest prognostic indicators of poor prognosis by univariate and multivariate analyses. Borderline positive correlations were observed between RelA and pI kappaB alpha or pIKK alpha/beta expression. In this cohort of early-stage NSCLC patients, molecular markers, especially composite application of multiple biomarkers (both nuclear RelA and cytoplasmic pI kappaB-alpha expression) that independently predict overall survival have been identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.